Trials / Active Not Recruiting
Active Not RecruitingNCT04189614
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cofetuzumab Pelidotin | Intravenous (IV) infusion |
Timeline
- Start date
- 2020-02-13
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2019-12-06
- Last updated
- 2026-03-24
Locations
26 sites across 6 countries: United States, Israel, Japan, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04189614. Inclusion in this directory is not an endorsement.